Breakthrough Designation and Community Adoption Potential

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses how Breakthrough Therapy Designation and the convenience of subcutaneous dosing could influence adoption of amivantamab in community oncology practice for head and neck squamous cell carcinoma (HNSCC). He notes that administration takes under 10 minutes and, combined with the Breakthrough Therapy Designation and the efficacy data from OrigAMI-4, may support rapid regulatory approval and clinical uptake. Dr. Swiecicki points out that amivantamab is already available in the clinic for non-small cell lung cancer (NSCLC), which could allow a quicker formulary pivot to HNSCC once approved. He characterizes the agent as well tolerated overall and suggests that its combination of efficacy, tolerability, and convenient dosing may lead to swift adoption and meaningful improvement in outcomes for a patient population he describes as desperately in need of better treatment options.